Development Level

Tbio 108 | 10,625
Tdark 21 | 7,003
Tchem 9 | 1,890
Tclin 1 | 602

IMPC Term

preweaning lethality, incomple... 5 | 260
abnormal behavior 3 | 226
abnormal retinal pigmentation 3 | 61
decreased body weight 3 | 174
preweaning lethality, complete... 3 | 633
abnormal embryo size 2 | 112
abnormal retina morphology 2 | 100
decreased T cell number 2 | 31
decreased bone mineral content 2 | 157
decreased bone mineral density 2 | 126
decreased circulating HDL chol... 2 | 77
decreased circulating iron lev... 2 | 25
decreased grip strength 2 | 123
decreased lean body mass 2 | 195
decreased mature B cell number 2 | 25
decreased total body fat amoun... 2 | 186
hyperactivity 2 | 108
improved glucose tolerance 2 | 56
increased blood urea nitrogen ... 2 | 44
increased circulating alkaline... 2 | 119
increased circulating calcium ... 2 | 32
increased mean corpuscular hem... 2 | 93
increased mean corpuscular vol... 2 | 91
abnormal behavioral response t... 1 | 52
abnormal response to tactile s... 1 | 16
abnormal retinal vasculature m... 1 | 15
abnormal vibrissa morphology 1 | 17
decreased CD4-positive, CD25-p... 1 | 24
decreased CD8-positive, alpha-... 1 | 26
decreased IgE level 1 | 3
decreased IgG1 level 1 | 4
decreased Ly6C high monocyte n... 1 | 18
decreased NK T cell number 1 | 28
decreased blood urea nitrogen ... 1 | 31
decreased body length 1 | 108
decreased caudal vertebrae num... 1 | 49
decreased circulating LDL chol... 1 | 37
decreased circulating alanine ... 1 | 53
decreased circulating aspartat... 1 | 27
decreased circulating calcium ... 1 | 33
decreased circulating choleste... 1 | 85
decreased circulating creatini... 1 | 31
decreased circulating free fat... 1 | 39
decreased circulating fructosa... 1 | 31
decreased circulating glucose ... 1 | 121
decreased circulating insulin ... 1 | 75
decreased circulating serum al... 1 | 79
decreased circulating triglyce... 1 | 83
decreased dendritic cell numbe... 1 | 3
decreased eosinophil cell numb... 1 | 41
decreased hematocrit 1 | 25
decreased hemoglobin content 1 | 53
decreased immature NK cell num... 1 | 1
decreased leukocyte cell numbe... 1 | 54
decreased mean corpuscular hem... 1 | 19
decreased monocyte cell number 1 | 28
enlarged heart 1 | 111
enlarged lymph nodes 1 | 27
hypoactivity 1 | 89
impaired righting response 1 | 19
increased B cell number 1 | 23
increased B-1a cell number 1 | 2
increased CD4-positive, CD25-p... 1 | 18
increased CD4-positive, alpha ... 1 | 15
increased KLRG1-positive NK ce... 1 | 9
increased Ly6C high monocyte n... 1 | 12
increased NK cell number 1 | 19
increased body length 1 | 20
increased bone mineral density 1 | 52
increased circulating free fat... 1 | 17
increased circulating phosphat... 1 | 24
increased circulating sodium l... 1 | 71
increased circulating total pr... 1 | 20
increased effector memory CD4-... 1 | 15
increased effector memory CD8-... 1 | 14
increased hematocrit 1 | 36
increased hemoglobin content 1 | 45
increased lean body mass 1 | 107
increased mature B cell number 1 | 12
increased mature NK cell numbe... 1 | 1
increased monocyte cell number 1 | 27
increased plasmacytoid dendrit... 1 | 1
increased transitional stage T... 1 | 1
male infertility 1 | 62
microphthalmia 1 | 15
prolonged PQ interval 1 | 3
tremors 1 | 34

Disease

osteosarcoma 85 | 7,933
ovarian cancer 80 | 8,492
medulloblastoma, large-cell 68 | 6,234
glioblastoma 65 | 5,572
psoriasis 53 | 6,685
atypical teratoid / rhabdoid tumor 48 | 4,369
lung cancer 47 | 4,473
primitive neuroectodermal tumor 46 | 3,031
invasive ductal carcinoma 44 | 2,950
non-small cell lung cancer 43 | 2,798
lung carcinoma 41 | 2,844
subependymal giant cell astrocytoma 41 | 2,287
pilocytic astrocytoma 40 | 3,086
lung adenocarcinoma 39 | 2,714
Carcinoma 38 | 2,147
Breast cancer 35 | 3,099
intraductal papillary-mucinous neoplasm (IPMN) 35 | 3,289
pediatric high grade glioma 35 | 2,712
intraductal papillary-mucinous carcinoma (IPMC) 34 | 2,988
oligodendroglioma 34 | 2,849
ulcerative colitis 34 | 2,087
ependymoma 31 | 2,514
intraductal papillary-mucinous adenoma (IPMA) 31 | 2,956
malignant mesothelioma 31 | 3,163
adult high grade glioma 29 | 2,148
group 4 medulloblastoma 29 | 1,875
Cancer 26 | 2,346
astrocytic glioma 25 | 2,241
ductal carcinoma in situ 24 | 1,745
interstitial cystitis 24 | 2,299
Pick disease 23 | 1,893
pituitary cancer 23 | 1,972
cystic fibrosis 22 | 1,670
breast carcinoma 21 | 1,614
group 3 medulloblastoma 21 | 2,254
medulloblastoma 21 | 1,524
pancreatic cancer 21 | 2,300
sonic hedgehog group medulloblastoma 18 | 1,482
astrocytoma 17 | 1,493
acute quadriplegic myopathy 15 | 1,157
primary Sjogren syndrome 15 | 789
spina bifida 15 | 1,064
colon cancer 14 | 1,475
Intellectual disability 13 | 573
cutaneous lupus erythematosus 13 | 1,056
posterior fossa group B ependymoma 13 | 1,530
atypical teratoid/rhabdoid tumor 12 | 1,095
pancreatic ductal adenocarcinoma liver metastasis 12 | 1,795
aldosterone-producing adenoma 10 | 664
juvenile dermatomyositis 10 | 1,189
primary pancreatic ductal adenocarcinoma 10 | 1,271
tuberculosis 10 | 1,563
Rheumatoid Arthritis 9 | 1,171
Waldenstrons macroglobulinemia 9 | 765
active Crohn's disease 9 | 918
dermatomyositis 9 | 967
gastric cancer 9 | 436
Amyotrophic Lateral Sclerosis 8 | 432
Multiple myeloma 8 | 1,328
fibroadenoma 8 | 557
gastric carcinoma 8 | 832
mucosa-associated lymphoid tissue lymphoma 8 | 480
nasopharyngeal carcinoma 8 | 1,056
posterior fossa group A ependymoma 8 | 1,511
tuberculosis and treatment for 6 months 8 | 686
Alzheimer's disease 7 | 644
adrenocortical carcinoma 7 | 1,427
autosomal dominant Emery-Dreifuss muscular dystrophy 7 | 499
diabetes mellitus 7 | 1,663
esophageal adenocarcinoma 7 | 737
hepatocellular carcinoma 7 | 550
progressive supranuclear palsy 7 | 674
Endometriosis 6 | 535
IGA Glomerulonephritis 6 | 454
Polycystic Ovary Syndrome 6 | 335
interstitial lung disease 6 | 292
pancreatic carcinoma 6 | 567
Aarskog-Scott syndrome 5 | 11
Atopic dermatitis 5 | 944
Down syndrome 5 | 548
HIV Infections 5 | 100
sarcoidosis 5 | 368
Crohn's disease 4 | 304
Duchenne muscular dystrophy 4 | 602
Mental Retardation, X-Linked 4 | 23
Neuropathy 4 | 210
Prostatic Neoplasms 4 | 471
Vascular disease 4 | 281
glioblastoma multiforme 4 | 347
hereditary spastic paraplegia 4 | 313
non primary Sjogren syndrome sicca 4 | 840
tuberculosis and treatment for 3 months 4 | 327
Hypertensive disease 3 | 193
Kidney disease 3 | 397
Multiple Sclerosis 3 | 498
Schizophrenia 3 | 503
Type 2 diabetes mellitus 3 | 192
chronic lymphocytic leukemia 3 | 244
chronic rhinosinusitis 3 | 512
periodontitis 3 | 269

Tissue

Cardiovascular System 139 | 17,958
Digestive Tract 139 | 18,473
Female tissues 139 | 18,647
Liver and Pancreas 139 | 18,136
Male tissues 139 | 17,969
Nervous System 139 | 18,561
Blood and immune system 138 | 17,995
Endocrine System 138 | 18,512
Respiratory system 138 | 17,484
Urinary Tract 138 | 18,444
Skin and soft tissues 137 | 18,115

Target Family

Non-IDG 73 | 11,969
Enzyme 63 | 4,146
Kinase 3 | 634

Reactome Pathway

Rho GTPase cycle 139 | 139
Signal Transduction 2,516 | 2,516
Immune System 2,184 | 2,184
Metabolism 2,132 | 2,132
Gene Expression 1,755 | 1,755
Metabolism of proteins 1,545 | 1,545
Innate Immune System 1,376 | 1,376
Signaling by GPCR 1,330 | 1,330
Developmental Biology 1,029 | 1,029
GPCR downstream signaling 1,015 | 1,015
Post-translational protein mod... 1,005 | 1,005
Adaptive Immune System 939 | 939
Disease 856 | 856
Generic Transcription Pathway 852 | 852
Cytokine Signaling in Immune s... 804 | 804
Metabolism of lipids and lipop... 797 | 797
Vesicle-mediated transport 705 | 705
Hemostasis 669 | 669
Transmembrane transport of sma... 669 | 669
Membrane Trafficking 608 | 608
Cell Cycle 573 | 573
Axon guidance 542 | 542
Neutrophil degranulation 542 | 542
Signaling by Interleukins 501 | 501
Cell Cycle, Mitotic 471 | 471
Signalling by NGF 468 | 468
GPCR ligand binding 456 | 456
Gastrin-CREB signalling pathwa... 436 | 436
Class I MHC mediated antigen p... 431 | 431
Olfactory Signaling Pathway 430 | 430
Fc epsilon receptor (FCERI) si... 424 | 424
Cellular responses to stress 416 | 416
DAP12 interactions 410 | 410
Infectious disease 392 | 392
NGF signalling via TRKA from t... 379 | 379
Signaling by Rho GTPases 378 | 378
Signaling by PDGF 368 | 368
Diseases of signal transductio... 360 | 360
Signaling by EGFR 356 | 356
Transcriptional Regulation by ... 356 | 356
Metabolism of amino acids and ... 354 | 354
DAP12 signaling 347 | 347
Downstream signal transduction 344 | 344
Neuronal System 343 | 343
Organelle biogenesis and maint... 334 | 334
Signaling by VEGF 330 | 330
Signaling by SCF-KIT 328 | 328
Class A/1 (Rhodopsin-like rece... 322 | 322
VEGFA-VEGFR2 Pathway 322 | 322
FCERI mediated MAPK activation 317 | 317
Signaling by Insulin receptor 313 | 313
Antigen processing: Ubiquitina... 302 | 302
Extracellular matrix organizat... 292 | 292
Signaling by Type 1 Insulin-li... 291 | 291
Signaling by Wnt 291 | 291
IGF1R signaling cascade 290 | 290
IRS-related events triggered b... 290 | 290
Insulin receptor signalling ca... 289 | 289
Metabolism of carbohydrates 288 | 288
DNA Repair 286 | 286
IRS-mediated signalling 286 | 286
MAPK family signaling cascades 284 | 284
Signaling by the B Cell Recept... 283 | 283
Asparagine N-linked glycosylat... 282 | 282
SLC-mediated transmembrane tra... 280 | 280
Deubiquitination 278 | 278
Interferon Signaling 275 | 275
Platelet activation, signaling... 274 | 274
NCAM signaling for neurite out... 269 | 269
M Phase 267 | 267
Interleukin-3, 5 and GM-CSF si... 263 | 263
RET signaling 262 | 262
Signalling to ERKs 255 | 255
Interleukin-2 signaling 254 | 254
Immunoregulatory interactions ... 252 | 252
VEGFR2 mediated cell prolifera... 250 | 250
RHO GTPase Effectors 249 | 249
Signalling to RAS 248 | 248
Interleukin receptor SHC signa... 247 | 247
G alpha (i) signalling events 245 | 245
Signaling by Leptin 245 | 245
Fatty acid, triacylglycerol, a... 244 | 244
Prolonged ERK activation event... 244 | 244
MAPK1/MAPK3 signaling 243 | 243
Frs2-mediated activation 242 | 242
HIV Infection 242 | 242
ARMS-mediated activation 241 | 241
Signalling to p38 via RIT and ... 241 | 241
Chromatin modifying enzymes 237 | 237
Chromatin organization 237 | 237
GRB2 events in EGFR signaling 237 | 237
RAF/MAP kinase cascade 237 | 237
SHC1 events in EGFR signaling 237 | 237
SOS-mediated signalling 237 | 237
Processing of Capped Intron-Co... 235 | 235
Biological oxidations 215 | 215
Keratinization 213 | 213
Transmission across Chemical S... 210 | 210
rRNA processing 209 | 209
Ion channel transport 204 | 204
Ub-specific processing proteas... 203 | 203

This is where graphics are reside..
Name Gene Development Level Target Family Log Novelty  Pubmed Score  Antibody Count  Knowledge Availability 
Rho GDP-dissociation inhibitor 3 ARHGDIG Tbio Non-IDG -0.79022 8.54 95
Rho GTPase-activating protein 9 ARHGAP9 Tbio Enzyme -1.72520 53.3 32
Rho guanine nucleotide exchange factor 10-like protein ARHGEF10L Tdark Non-IDG 0.19 0.86 22
DEP domain-containing protein 1B DEPDC1B Tbio Non-IDG -0.67840 5.71 70
Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 1 ARAP1 Tbio Non-IDG -0.97819 13.6 86
StAR-related lipid transfer protein 13 STARD13 Tbio Non-IDG -2.01004 73.4 68
Rho GTPase-activating protein 17 ARHGAP17 Tbio Enzyme -1.80007 60.0 111
Ras-related C3 botulinum toxin substrate 2 RAC2 Tchem Enzyme -2.87547 633.7 216
Unconventional myosin-IXb MYO9B Tbio Non-IDG -1.66965 54.7 76
Unconventional myosin-IXa MYO9A Tdark Non-IDG -0.81625 8.59 18